Results 11 to 20 of about 34,512 (245)

Gene of the month:IDH1 [PDF]

Journal of Clinical Pathology, 2020
Isocitrate dehydrogenase 1(IDH1) encodes a protein which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate. Mutant IDH1 favours the production of 2-hydroxyglutarate, an oncometabolite with multiple downstream effects which promote tumourigenesis.IDH1mutations have been described in a number of neoplasms most notably low-grade ...
Cassandra Bruce-Brand, Dhirendra Govender   +1 more
openaire   +3 more sources

IDH1: Linking Metabolism and Epigenetics [PDF]

Frontiers in Genetics, 2018
Mutations in genes encoding enzymes of the tricarboxylic acid cycle often contribute to cancer development and progression by disrupting cell metabolism and altering the epigenetic landscape. This is exemplified by the isoforms of isocitrate dehydrogenase (IDH1/2), which metabolize isocitrate to α-Ketoglutarate (α-KG).
Silvia Raineri, Silvia Raineri, Jane Mellor, Jane Mellor   +3 more
openaire   +5 more sources

IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5 [PDF]

Open Biology, 2018
Mutation in isocitrate dehydrogenase (IDH) leads to an aberrant function of the enzyme, leading to the production of hydroxyglutarate, as well as changes in cellular metabolism, DNA methylation and histone modification.
Bingdi Yan, Yanbing Hu, Tiangang Ma, Yanjun Wang   +3 more
doaj   +1 more source

Metabolism, Gliomas, andIDH1 [PDF]

New England Journal of Medicine, 2010
A mutation in IDH1, which encodes an isocitrate dehydrogenase, is associated with susceptibility to glioma. This mutation results in an acquired enzyme activity that points to a potential biomarker of the mutant tumor.
Smeitink, J.A.M., Smeitink, J.A.M.
openaire   +4 more sources

Mutant IDH1 and thrombosis in gliomas [PDF]

Acta Neuropathologica, 2016
Mutant isocitrate dehydrogenase 1 (IDH1) is common in gliomas, and produces D-2-hydroxyglutarate (D-2-HG). The full effects of IDH1 mutations on glioma biology and tumor microenvironment are unknown. We analyzed a discovery cohort of 169 World Health Organization (WHO) grade II-IV gliomas, followed by a validation cohort of 148 cases, for IDH1 ...
Dusten Unruh, Steven R. Schwarze, Laith Khoury, Cheddhi Thomas, Meijing Wu, Li Chen, Rui Chen, Yinxing Liu, Margaret A. Schwartz, Christina Amidei, Priya Kumthekar, Carolina G. Benjamin, Kristine Song, Caleb Dawson, Joanne M. Rispoli, Girish Fatterpekar, John G. Golfinos, Douglas Kondziolka, Matthias Karajannis, Donato Pacione, David Zagzag, Thomas McIntyre, Matija Snuderl, Craig Horbinski   +23 more
openaire   +3 more sources

Correlation of IDH1, p53 and Ki-67 immunoexpression levels with morphological, clinical prognostic parameters and preoperative/postoperative radiological findings and response to treatment in high-grade glial tumor case

Medicine Science, 2023
In this study, we aimed to investigate the prognostic factors affecting survival in adult patients with high-grade glial tumors. The retrospective study included 79 consecutive patients who were referred to our clinic for adjuvant radiotherapy ...
Murtaza Parvizi, Ulkun Unlu Unsal, Olcay Ak Nalbant, Derya Demir, Murat Akyol, Aydin Isisag   +5 more
doaj   +1 more source

Retrospective and Randomized Analysis of Influence and Correlation of Clinical and Molecular Prognostic Factors in a Mono-Operative Series of 122 Patients with Glioblastoma Treated with STR or GTR

Brain Sciences, 2020
Glioblastoma is a solid, infiltrating, and the most frequent highly malignant primary brain tumor. Our aim was to find the correlation between sex, age, preoperative Karnofsky performance status (KPS), presenting with seizures, and extent of resection ...
Maurizio Salvati, Placido Bruzzaniti, Michela Relucenti, Mariagrazia Nizzola, Pietro Familiari, Marco Giugliano, Anthony Kevin Scafa, Santi Galletta, Xiaobo Li, Rui Chen, Claudio Barbaranelli, Alessandro Frati, Antonio Santoro   +12 more
doaj   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

IDH1‐mutant cancer cells are sensitive to cisplatin and an IDH1‐mutant inhibitor counteracts this sensitivity [PDF]

The FASEB Journal, 2018
IntroductionIsocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer and the presence of a mutation is associated with improved responses to irradiation and chemotherapy in solid tumor cells. Mutated IDH1 (IDH1MUT) enzymes consume NADPH to produce D‐2‐hydroxyglutarate (D‐2HG) resulting in a decreased reducing power needed for ...
Khurshed, Mohammed, Aarnoudse, Niels, Hulsbos, Renske, Hira, Vashendriya V. V., Laarhoven, Hanneke WM van, Wilmink, Johanna W, Molenaar, Remco J., Noorden, Cornelis J. F. van   +7 more
openaire   +3 more sources

Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis

Open Medicine, 2022
The present study intends to clarify the hypothesis that isocitrate dehydrogenase 1 (IDH1) mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis through the in vitro and in vivo experiments.
Su Li, Huang Yi, Zheng Lei, Zhu Zhifa, Wu Yue, Li Ping   +5 more
doaj   +1 more source